Physician profile
Michael Bageac
NPI 1811984701
$4,604.48
in general payments reported to CMS, 2019-2025
28 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $684 · 2021: $694 · 2022: $1,078 · 2023: $677 · 2024: $208 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $867.56 | 2019-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $655.20 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $567.69 | 2019-2023 | Camzyos, Eliquis |
| Boston Scientific Corporation | $462.07 | 2019-2024 | Watchman Flx, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $438.11 | 2019-2025 | |
| Amgen INC. | $272.22 | 2019-2023 | Repatha |
| Pfizer INC. | $198.07 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.81 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $177.47 | 2021-2023 | Verquvo |
| Abiomed | $128.83 | 2025 | |
| Sanofi-Aventis U.S. LLC | $115.07 | 2019-2023 | |
| Amarin Pharma, INC. | $114.18 | 2019 | |
| Novo Nordisk INC | $112.72 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $60.52 | 2019-2024 | Evkeeza |
| Irhythm Technologies, INC. | $35.61 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $27.53 | 2019-2021 | |
| Scpharmaceuticals INC. | $26.76 | 2025 | |
| Abbott Laboratories | $16.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.96 | 2024 | Amvuttra |
| Esperion Therapeutics, INC. | $14.96 | 2020 | |
| Medtronic Vascular, INC. | $14.94 | 2020 | |
| Philips North America LLC | $14.76 | 2022 | |
| Lundbeck LLC | $14.61 | 2019 | |
| Gilead Sciences, INC. | $14.58 | 2019 | |
| Bridgebio Pharma, INC. | $14.26 | 2025 | Attruby |
| Astellas Pharma US INC | $14.20 | 2020 | |
| Daiichi Sankyo INC. | $13.89 | 2022 | |
| Acarix USA INC. | $13.21 | 2024 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bageac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.